title: [Use of troponin analysis in Norwegian hospitals].
abstract: BACKGROUND
  A highly sensitive troponin T analysis became available in Norway in 2009. The Norwegian Society of Medical Biochemistry believed that a national strategy for implementation of the analysis would ensure a more coherent practice for diagnosing acute myocardial infarction (AMI).
  
  
  METHODS
  70 laboratories were requested to identify (in a questionnaire) the type of assay used, routines for reporting results of analyses, internal quality control programmes (IQA) and local cut-off values for making the diagnosis AMI.
  
  
  RESULTS
  62 laboratories responded and 57 of these analyzed troponins; 60 % used troponin T and 40 % troponin I. 82 % of laboratories were familiar with the decision limit used for diagnosing AMI at their hospital; 43 % of troponin T laboratories used the cut-off recommended by the Norwegian Society of Cardiology (0.03 microg/l) to diagnose AMI. For the two most used troponin I methods (16 laboratories) eight different cut-off values were reported. 24 % (troponin T) and 35 % (troponin I) of laboratories performed IQA at a concentration similar or lower than the local decision limit used when diagnosing AMI. 73 % (troponin T) and 54 % (troponin I) of laboratories used the lower limit of quantification as the lower cut-off value for reportable results.
  
  
  CONCLUSIONS
  In Norwegian hospitals, users of the same methods for analysis of troponin have different routines for interpreting, IQA and reporting of results. Patient diagnoses may therefore vary according to the hospital used. The Norwegian Society of Medical Biochemistry has developed recommendations for implementation of troponin analyses in Norwegian laboratories.
authors.affiliation: Laboratorium for klinisk biokjemi, Haukeland universitetssykehus, 5021 Bergen, Norway. kristin.moberg.aakre@helse-bergen.no
authors.forename: Kristin M
authors.initials: KM
authors.lastname: Aakre
authors.forename: Sverre
authors.initials: S
authors.lastname: Landaas
authors.forename: Tor-Arne
authors.initials: TA
authors.lastname: Hagve
mesh_terms: D015415:Biomarkers / Q000097:blood*; D006801:Humans; D007755:Laboratories, Hospital / Q000592:standards; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis*; D009664:Norway; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011785:Quality Assurance, Health Care; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires; D014336:Troponin / Q000097:blood*; D019210:Troponin I / Q000097:blood; D020107:Troponin T / Q000097:blood
chemical_list: D015415:Biomarkers; D014336:Troponin; D019210:Troponin I; D020107:Troponin T